Drug Trial Radar · NCT05774405
Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients
Last checked: Nov 19, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,169
Actual
Start
Jul 1, 2020
Primary completion
Jul 31, 2021
Study completion Jul 31, 2021
Sponsor
- Lead sponsor
- Istanbul University - CerrahpasaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Turkish Menopause and Osteoporosis Society; Karakoy Rotary Club; Rebul Pharmacy
- First posted
- Mar 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized placebo-controlled study is to investigate the short-term effects of transdermal estrogen therapy on postmenopausal women with COVID-19 disease. The main question\[s\] it aims to answer are: * the clinical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease * the biochemical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease All participants received favipiravir for a week according to the national guidelines published by the Health Ministry of Turkish Republic at that time. As an intervention, transdermal estradiol patch (7.8 mg patch/week) was applied for 14 days on the upper buttock of the patients in experimental arm. As a placebo, hydrogel patch (adhesive hydrogel patch/week) was applied to the female patients for 14 days. Researchers compared experimental and control groups to see if the impact of adding estrogen on the clinical course of Covid-19 disease
Conditions
- COVID-19
- Hormone Replacement Therapy
Interventions
Climara 0.1Mg/24Hr Transdermal SystemDrug
Transdermal estradiol patch is used.
Hydrogel patchOther
Adhesive Hydrogel patch
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evidence of disease progression for mild casesTime frame: 15 days
- Evidence of disease progression for moderate and severe casesTime frame: 15 days
- Kidney function testsTime frame: 15 days
- PlateletTime frame: 15 days
- Markers of coagulationTime frame: 15 days
- Marker of inflammationTime frame: 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istanbul University-Cerrahpasa
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.